市場調查報告書
商品編碼
1030412

全球膠質母細胞瘤治療市場:按治療、藥物類別、最終用戶、地區預測(2021-2027)

Global Glioblastoma Multiforme Treatment Market Size study, by Treatment, by Drug class, by End use, and Regional Forecasts 2021-2027

出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

2020年膠質母細胞瘤多態性治療的市場規模約為21.4億美元,預計2021年至2027年的預測期內增長率將超過8.6%。我是。

膠質母細胞瘤多態性是一種始於人腦的嚴重癌症。市場受到膠質母細胞瘤多態性患病率增加和腦腫瘤發病率增加的推動。此外,新療法和聯合療法的研發增加和更高的批准率為全球膠質母細胞瘤治療行業提供了新的機遇。另一方面,膠質母細胞瘤多態性沒有有效的治療方法,與藥物開發相關的高成本和嚴格規定可能會阻礙 2021-2027 預測期內的市場增長。

本報告探討了膠質母細胞瘤治療市場,並提供全面的市場概況、市場分析、治療/藥物類別/最終用戶/區域分析和競爭格局。提供信息。

目錄

第 1 章執行摘要

第二章全球膠質母細胞瘤治療市場的定義和範圍

第 3 章全球膠質母細胞瘤治療市場動態

  • 膠質母細胞瘤治療市場影響分析(2019-2027)

第 4 章全球膠質母細胞瘤治療市場行業分析

  • 波特的 5 力模型
  • PEST 分析
  • 投資採用模式
  • 分析師建議和結論

按治療方法分列的第 5 章全球膠質母細胞瘤治療市場

  • 市場快照
  • 按治療分類的全球膠質母細胞瘤治療市場:潛力分析
  • 全球膠質母細胞瘤治療市場的估計和預測(2018-2027)(10億美元)
  • 多態性膠質母細胞瘤治療市場,細分市場分析
    • 手術
    • 放射治療
    • 化療
    • 靶向治療
    • 腫瘤治療野戰治療
    • 免疫療法

按藥物類別劃分的第 6 章全球膠質母細胞瘤治療市場

a. 市場快照

  • 按藥物類別劃分的全球膠質母細胞瘤治療市場:潛力分析
  • 按藥物類別對全球膠質母細胞瘤治療市場的估計和預測(2018-2027)(10億美元)
  • 多態性膠質母細胞瘤治療市場,細分市場分析
    • 替莫唑胺
    • 貝伐單抗
    • 洛莫司汀
    • 卡莫司汀威化餅
    • 其他

最終用戶第 7 章全球膠質母細胞瘤治療市場

b. 市場快照

  • 最終用戶的全球膠質母細胞瘤治療市場:潛在分析
  • 最終用戶對全球膠質母細胞瘤治療市場的估計和預測(2018-2027)(10 億美元)
  • 多態性膠質母細胞瘤治療市場,細分市場分析
    • 醫院
    • 診所
    • 門診手術中心

第 8 章全球膠質母細胞瘤治療市場,區域分析

  • 區域市場快照
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 意大利
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 巴西
    • 墨西哥
  • 其他

第9章衝突信息

  • 頂級市場策略
  • 公司簡介
    • Merck & Co., Inc.
    • Sumitomo Dainippon Pharma Oncology, Inc.(Boston Biomedical, Inc.)
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • Amgen, Inc.
    • Arbor Pharmaceuticals, LLC
    • Amneal Pharmaceuticals
    • Karyopharm Therapeutics, Inc.

第10章 調查流程

目錄

Global Glioblastoma Multiforme Treatment Market is valued approximately at USD 2.14 Billion in 2020 and is anticipated to grow with a healthy growth rate of more than 8.6% over the forecast period 2021-2027. Glioblastoma Multiforme is a severe form of cancer which begins within the human brain. The global Glioblastoma Multiforme Treatment market is being driven by rising prevalence of glioblastoma multiforme and increase in incidences of brain tumors. Furthermore, the rising research and development, and growth in rate of approval for novel therapy and combination therapy will provide new opportunities for the global Glioblastoma Multiforme Treatment industry. For instance, according to National Brain Tumor society, in year 2020, there were 700,000 people suffering with primary brain tumor in the United States and it is anticipated that approximately 85,000 more people will be diagnosed by year end 2021. Also, in June 2019, the U.S. FDA had approved Pfizer's Zirabev, which is a biosimilar for Avastin, and used for the treatment of the recurrent glioblastoma, colorectal cancer and NSCLC, and among others. Also, in July 2020, the U.S. FDA granted fast track approval for designation to Denovo biopharma's DB102 (enzastaurin) to treat new patients who are diagnosed with glioblastoma. As a result, increased approvals for novel therapy and combination therapy will serve as a catalyst for the Glioblastoma Multiforme Treatment industry in the future. However, lack of effective therapies for glioblastoma multiforme and high cost associated with the development of drug and stringent regulations, may impede market growth over the forecast period of 2021-2027.

Asia Pacific, North America, Europe, Latin America, and Rest of the World are the key region considered for the global Glioblastoma Multiforme Treatment Market. Strong government support in order for the development of healthcare sector, rising awareness about the rare disorders, and easy accessibility of quality medical facility makes North America the leading region across the world in terms of market share. Whereas Asia pacific is also anticipated to exhibit the highest growth rate over the forecast period 2021-2027, due to entry of generics of temozolomide in the market, improving economy, rising geriatric population, and growing investments in the healthcare sector in the region.

Major market player included in this report are:

Merck & Co., Inc.

Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)

Teva Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd.

Hoffmann-La Roche Ltd.

Pfizer, Inc.

Amgen, Inc.

Arbor Pharmaceuticals, LLC

Amneal Pharmaceuticals

Karyopharm Therapeutics, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Treatment:

Surgery

Radiation Therapy

Chemotherapy

Targeted Therapy

Tumor Treating Fields Therapy

Immunotherapy

By Drug class:

Temozolomide

Bevacizumab

Lomustine

Carmustine Wafers

Others

By End use:

Hospitals

Clinics

Ambulatory Surgical Centers

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019

Base year - 2020

Forecast period - 2021 to 2027.

Target Audience of the Global Glioblastoma Multiforme Treatment Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
    • 1.2.1. Glioblastoma Multiforme Treatment Market , by Region, 2019-2027 (USD Billion)
    • 1.2.2. Glioblastoma Multiforme Treatment Market , by Treatment , 2019-2027 (USD Billion)
    • 1.2.3. Glioblastoma Multiforme Treatment Market , by Drug class, 2019-2027 (USD Billion)
    • 1.2.4. Glioblastoma Multiforme Treatment Market , by End use, 2019-2027 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Glioblastoma Multiforme Treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Glioblastoma Multiforme Treatment Market Dynamics

  • 3.1. Glioblastoma Multiforme Treatment Market Impact Analysis (2019-2027)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising prevalence of glioblastoma multiforme
      • 3.1.1.2. Increase in incidences of brain tumours
    • 3.1.2. Market Restraint
      • 3.1.2.1. Lack of effective therapies for glioblastoma multiforme
      • 3.1.2.2. High cost associated with the development of drug and stringent regulations
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growth in rate of approval for novel therapy and combination therapy

Chapter 4. Global Glioblastoma Multiforme Treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2027)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion

Chapter 5. Global Glioblastoma Multiforme Treatment Market , by Treatment

  • 5.1. Market Snapshot
  • 5.2. Global Glioblastoma Multiforme Treatment Market by Treatment , Performance - Potential Analysis
  • 5.3. Global Glioblastoma Multiforme Treatment Market Estimates & Forecasts by Treatment 2018-2027 (USD Billion)
  • 5.4. Glioblastoma Multiforme Treatment Market , Sub Segment Analysis
    • 5.4.1. Surgery
    • 5.4.2. Radiation Therapy
    • 5.4.3. Chemotherapy
    • 5.4.4. Targeted Therapy
    • 5.4.5. Tumor Treating Fields Therapy
    • 5.4.6. Immunotherapy

Chapter 6. Global Glioblastoma Multiforme Treatment Market , by Drug Class

a. Market Snapshot

  • 6.1. Global Glioblastoma Multiforme Treatment Market by Drug Class, Performance - Potential Analysis
  • 6.2. Global Glioblastoma Multiforme Treatment Market Estimates & Forecasts by Drug class2018-2027 (USD Billion)
  • 6.3. Glioblastoma Multiforme Treatment Market , Sub Segment Analysis
    • 6.3.1. Temozolomide
    • 6.3.2. Bevacizumab
    • 6.3.3. Lomustine
    • 6.3.4. Carmustine Wafers
    • 6.3.5. Others

Chapter 7. Global Glioblastoma Multiforme Treatment Market , by End use

b. Market Snapshot

  • 7.1. Global Glioblastoma Multiforme Treatment Market by End use, Performance - Potential Analysis
  • 7.2. Global Glioblastoma Multiforme Treatment Market Estimates & Forecasts by End use 2018-2027 (USD Billion)
  • 7.3. Glioblastoma Multiforme Treatment Market , Sub Segment Analysis
    • 7.3.1. Hospitals
    • 7.3.2. Clinics
    • 7.3.3. Ambulatory Surgical Centers

Chapter 8. Global Glioblastoma Multiforme Treatment Market , Regional Analysis

  • 8.1. Glioblastoma Multiforme Treatment Market , Regional Market Snapshot
  • 8.2. North America Glioblastoma Multiforme Treatment Market
    • 8.2.1. U.S. Glioblastoma Multiforme Treatment Market
      • 8.2.1.1. Treatment breakdown estimates & forecasts, 2018-2027
      • 8.2.1.2. Drug class breakdown estimates & forecasts, 2018-2027
      • 8.2.1.3. End use breakdown estimates & forecasts, 2018-2027
    • 8.2.2. Canada Glioblastoma Multiforme Treatment Market
  • 8.3. Europe Glioblastoma Multiforme Treatment Market Snapshot
    • 8.3.1. U.K. Glioblastoma Multiforme Treatment Market
    • 8.3.2. Germany Glioblastoma Multiforme Treatment Market
    • 8.3.3. France Glioblastoma Multiforme Treatment Market
    • 8.3.4. Spain Glioblastoma Multiforme Treatment Market
    • 8.3.5. Italy Glioblastoma Multiforme Treatment Market
    • 8.3.6. Rest of Europe Glioblastoma Multiforme Treatment Market
  • 8.4. Asia-Pacific Glioblastoma Multiforme Treatment Market Snapshot
    • 8.4.1. China Glioblastoma Multiforme Treatment Market
    • 8.4.2. India Glioblastoma Multiforme Treatment Market
    • 8.4.3. Japan Glioblastoma Multiforme Treatment Market
    • 8.4.4. Australia Glioblastoma Multiforme Treatment Market
    • 8.4.5. South Korea Glioblastoma Multiforme Treatment Market
    • 8.4.6. Rest of Asia Pacific Glioblastoma Multiforme Treatment Market
  • 8.5. Latin America Glioblastoma Multiforme Treatment Market Snapshot
    • 8.5.1. Brazil Glioblastoma Multiforme Treatment Market
    • 8.5.2. Mexico Glioblastoma Multiforme Treatment Market
  • 8.6. Rest of The World Glioblastoma Multiforme Treatment Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. Merck & Co., Inc.
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
    • 9.2.3. Teva Pharmaceutical Industries Ltd.
    • 9.2.4. Sun Pharmaceutical Industries Ltd.
    • 9.2.5. Hoffmann-La Roche Ltd.
    • 9.2.6. Pfizer, Inc.
    • 9.2.7. Amgen, Inc.
    • 9.2.8. Arbor Pharmaceuticals, LLC
    • 9.2.9. Amneal Pharmaceuticals
    • 9.2.10. Karyopharm Therapeutics, Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 2. Global Glioblastoma Multiforme Treatment Market , report scope
  • TABLE 3. Global Glioblastoma Multiforme Treatment Market estimates & forecasts by region 2018-2027 (USD Billion)
  • TABLE 4. Global Glioblastoma Multiforme Treatment Market estimates & forecasts by Treatment 2018-2027 (USD Billion)
  • TABLE 5. Global Glioblastoma Multiforme Treatment Market estimates & forecasts by Drug class2018-2027 (USD Billion)
  • TABLE 6. Global Glioblastoma Multiforme Treatment Market estimates & forecasts by End use 2018-2027 (USD Billion)
  • TABLE 7. Global Glioblastoma Multiforme Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 8. Global Glioblastoma Multiforme Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 9. Global Glioblastoma Multiforme Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 10. Global Glioblastoma Multiforme Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 11. Global Glioblastoma Multiforme Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 12. Global Glioblastoma Multiforme Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 13. Global Glioblastoma Multiforme Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 14. Global Glioblastoma Multiforme Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 15. Global Glioblastoma Multiforme Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 16. Global Glioblastoma Multiforme Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 17. Global Glioblastoma Multiforme Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 18. Global Glioblastoma Multiforme Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 19. Global Glioblastoma Multiforme Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 20. Global Glioblastoma Multiforme Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 21. Global Glioblastoma Multiforme Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 22. Global Glioblastoma Multiforme Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 23. U.S. Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 24. U.S. Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 25. U.S. Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 26. Canada Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 27. Canada Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 28. Canada Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 29. UK Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 30. UK Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 31. UK Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 32. Germany Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 33. Germany Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 34. Germany Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 35. France Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 36. France Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 37. France Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 38. Spain Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 39. Spain Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 40. Spain Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 41. Italy Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 42. Italy Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 43. Italy Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 44. ROE Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 45. ROE Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 46. ROE Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 47. China Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 48. China Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 49. China Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 50. India Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 51. India Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 52. India Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 53. Japan Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 54. Japan Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 55. Japan Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 56. Australia Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 57. Australia Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 58. Australia Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 59. South Korea Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 60. South Korea Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 61. South Korea Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 62. ROPAC Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 63. ROPAC Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 64. ROPAC Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 65. Brazil Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 66. Brazil Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 67. Brazil Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 68. Mexico Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 69. Mexico Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 70. Mexico Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 71. ROLA Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 72. ROLA Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 73. ROLA Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 74. ROW Glioblastoma Multiforme Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 75. ROW Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 76. ROW Glioblastoma Multiforme Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 77. List of secondary sources used in the study of global Glioblastoma Multiforme Treatment Market .
  • TABLE 78. List of primary sources used in the study of global Glioblastoma Multiforme Treatment Market .
  • TABLE 79. Years considered for the study.
  • TABLE 80. Exchange rates considered.

LIST OF FIGURES

List of figures

  • FIG 1. Global Glioblastoma Multiforme Treatment Market , research methodology
  • FIG 2. Global Glioblastoma Multiforme Treatment Market , market estimation techniques
  • FIG 3. Global market size estimates & forecast methods
  • FIG 4. Global Glioblastoma Multiforme Treatment Market , key trends 2020
  • FIG 5. Global Glioblastoma Multiforme Treatment Market , growth prospects 2021-2027
  • FIG 6. Global Glioblastoma Multiforme Treatment Market , porters 5 force model
  • FIG 7. Global Glioblastoma Multiforme Treatment Market , pest analysis
  • FIG 8. Global Glioblastoma Multiforme Treatment Market , value chain analysis
  • FIG 9. Global Glioblastoma Multiforme Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 10. Global Glioblastoma Multiforme Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 11. Global Glioblastoma Multiforme Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 12. Global Glioblastoma Multiforme Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 13. Global Glioblastoma Multiforme Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 14. Global Glioblastoma Multiforme Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 15. Global Glioblastoma Multiforme Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 16. Global Glioblastoma Multiforme Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 17. Global Glioblastoma Multiforme Treatment Market , regional snapshot 2018 & 2027
  • FIG 18. North America Glioblastoma Multiforme Treatment Market 2018 & 2027 (USD Billion)
  • FIG 19. Europe Glioblastoma Multiforme Treatment Market 2018 & 2027 (USD Billion)
  • FIG 20. Asia-Pacific Glioblastoma Multiforme Treatment Market 2018 & 2027 (USD Billion)
  • FIG 21. Latin America Glioblastoma Multiforme Treatment Market 2018 & 2027 (USD Billion)
  • FIG 22. Global Glioblastoma Multiforme Treatment Market , company market share analysis (2020)